MedPath

Effect of injection of methotrexate or triamcinolone in the nail for treatment of nail psoriasis

Phase 3
Recruiting
Conditions
ail psoriasis.
Other psoriasis
L40.8
Registration Number
IRCT20140212016557N7
Lead Sponsor
Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
78
Inclusion Criteria

Patients between 16 and 70 years of age
Clinically- or pathologically confirmed nail psoriasis that have involvement of one or more fingernails with psoriasis

Exclusion Criteria

Patients with involvement of 5 or more nails
Patients who received systemic or topical medication (for nail) in the last 3 months
Patients with skin involvement of more than 20% that need systemic treatment
Patients with nail fungal infection
History of hypersensitivity reactions to lidocaine, triamcinolone, or methotrexate
Diabetic patients
Pregnancy
Lactation
Immunocompromised patients
Patients with active peptic ulcer, gastritis, ascitis, and pleural effusion
Concomitant use of hepatotoxic drugs, or drugs that interfere with methotrexate metabolism
Concomitant radiotherapy
Active or severe infection
Decreased pulmonary function
Renal failure

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Severity of nail involvement with psoriasis. Timepoint: At the beginning of treatment and weeks 3 ,6, 9, 12, 15, and 23. Method of measurement: modified Nail Psoriasis Severity Index (mNAPSI), measured by inspection and scoring of the severity of psoriasis features in nail matrix and bed.
Secondary Outcome Measures
NameTimeMethod
Quality of life index. Timepoint: At the beginning and end of treatment. Method of measurement: Dermatology quality of life index questionnaire.;Pain severity during injection. Timepoint: At the beginning of treatment and weeks 3 ,6, 9, 12, 15, and 23. Method of measurement: illustrated numerical rating scale.
© Copyright 2025. All Rights Reserved by MedPath